Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Magnus1 who wrote (10859)	8/16/2018 8:31:59 AM
From: donpat	1 Recommendation Recommended By HardToFind Respond to of 12873

NNVC own no IP...none....zilch. Just for the record. Play ball!!!! PS: They may own some, I hasten to add. But it isn't patented, I'm pretty sure. It could be in the future. That's my pitch and I'm sticking to it. The bull pen is getting ready for a new pitcher...some wiz named Irach.

To: Magnus1 who wrote (10859)	8/16/2018 10:42:28 AM
From: mattstat	1 Recommendation Recommended By HardToFind Read Replies (2) \| Respond to of 12873

Despite whatever you believe the cabal to be, it does not matter as much as the fundamental situation with NNVC. And we are not at 35 cents because of a cabal. Sadly, I had a friend in the bio-business look over NNVC the last couple weeks. And he has come to the conclusion that this company is in a very precarious situation even if the Cides prove themselves to work. He advised me to sell out if we see a pop to $1 or so. But he believes in the long run, this company is probably doomed (as 90% of most start ups). He did say the corporate structure with TheraCour is one of the most convoluted he has ever seen. That would have been a red flag for him day 1.

To: Magnus1 who wrote (10859)	8/16/2018 5:48:49 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

NNVC still owns it IP. NNVC has licensed TheraCour's IP for specific indications, and nothing more. Shingles is not among those indications, yet. The licensing agreement is very clear: 1. All nanoviricide IP belongs to TC. 2. All development requested by NNVC is paid for by NNVC. The R&D must be done by TC (with a 30% markup). The resultant patents all belong to TC. The production must be done by TC (with a 30% markup). All trade secrets belong to TC. NNVC may own some animal data that they pay outside parties to generate, but that is negotiated with the specific research institutions. Nothing has happens with the newest indication and so we don't know what is occurring. I have had several conversations with management, specifically Seymour. He indicated his frustration with the shingles licensing process and the fact that the lead indication of shingles was chosen over genital herpes. (You don't have to believe me, because I'm not going to produce those conversations or emails. NNVC isn't bankrupt. You're right. But their auditors did require NNVC to note in their latest filings that they may not have enough funds to continue operations for the coming 12 months. This is called a "going concern" warning. A "going concern" is a business that functions without the threat of liquidation for the foreseeable future, usually regarded as at least within 12 months. NNVC's status as a going concern is in question by the auditors today. Yidam was a different issue. Included in the Yidam lawsuit was precisely the handling to the initial licensing agreement, which Yidam thought was patently unfair and deceitful. I would encourage you to read the public filings. You obviously have not. Money is being paid to Theracour for services. Yes, and a lot more. Especially if we ever go into production, whether we make money or not. I don't like playing with facts out of my reach and drawing conclusions, that's called speculation. So is buying shares in NNVC called speculation. We do not know if it will ever be a going concern or a money-making business.